टोसिलिज़ुमैब के इंटरैक्शन

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including RENFLEXIS, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. (इन्फ्लिक्सिमैब लेबल, दवाओं के इंटरैक्शन)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (एडालिमुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (कैप्टोप्रिल लेबल, चेतावनियां)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (क्लैड्रिबिन लेबल, दवाओं के इंटरैक्शन)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (टैक्रोलिमस लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (डारुनाविर लेबल, दवाओं के इंटरैक्शन)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

…methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (निर्माट्रेल्विर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. (साइक्लोस्पोरिन लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (टोसिलिज़ुमैब लेबल, बॉक्स्ड चेतावनी)

In vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and simvastatin, metabolized by CYP3A4, showed up to a 28% and 57% decrease in exposure one week following a single dose of tocilizumab, respectively. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (एटाज़ानाविर लेबल, दवाओं के इंटरैक्शन)

Tocilizumab products have not been studied in combination with biological DMARDs such as TNF antagonists [see Dosage and Administration (2.2) ] . (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (एफाविरेंज़ लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (एफाविरेंज़, लैमिवुडिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (एम्लोडिपिन और ओल्मेसार्टन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (एम्लोडिपिन और वाल्सार्टन लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

In vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and simvastatin, metabolized by CYP3A4, showed up to a 28% and 57% decrease in exposure one week following a single dose of tocilizumab, respectively. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

In vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and simvastatin, metabolized by CYP3A4, showed up to a 28% and 57% decrease in exposure one week following a single dose of tocilizumab, respectively. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (टिनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (टेल्मिसार्टन और एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Therapeutic drug monitoring is recommended with concomitant use Immunosuppressant /neoplastic: everolimus ↑ immunosuppressants Co-administration of everolimus and PREZCOBIX or PREZCOBIX PED is not recommended. irinotecan Discontinue PREZCOBIX or PREZCOBIX PED at least 1 week prior to starting irinotecan therapy. (डारुनाविर और कोबिसिस्टैट लेबल, दवाओं के इंटरैक्शन)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (डेनोसुमैब लेबल, चेतावनियां और सावधानियां)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (नेफाज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (पेनिसिलामिन लेबल, चेतावनियां)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (फेनोफाइब्रिक एसिड लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (फेनोफाइब्रेट लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus ↑ Immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents. (फोसएम्प्रेनाविर लेबल, दवाओं के इंटरैक्शन)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (बेंडामुस्टिन लेबल, चेतावनियां और सावधानियां)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)

Lymphoma and Other Malignancies Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )]. (माइकोफेनोलेट लेबल, चेतावनियां और सावधानियां)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: cyclosporine, tacrolimus, sirolimus (rapamycin) ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir. (रिटोनाविर लेबल, दवाओं के इंटरैक्शन)

…Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)

Glipizide Decrease exposure Immunosuppressive Agents Cyclosporine Decrease exposure Tacrolimus Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when rifampin and tacrolimus are used concomitantly. (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (लेडिपासविर और सोफोसबुविर लेबल, चेतावनियां और सावधानियां)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (लेफ्लुनोमाइड लेबल, चेतावनियां और सावधानियां)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with KALETRA. (लोपिनाविर और रिटोनाविर लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

In vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and simvastatin, metabolized by CYP3A4, showed up to a 28% and 57% decrease in exposure one week following a single dose of tocilizumab, respectively. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (सोफोसबुविर और वेल्पाटासविर लेबल, चेतावनियां और सावधानियां)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (एक्सिटिनिब लेबल, चेतावनियां और सावधानियां)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (निफेडिपिन लेबल, सावधानियां)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (पिटावास्टेटिन लेबल, चेतावनियां और सावधानियां)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

CYP3A Substrates Immunosuppressants that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Posaconazole is a strong CYP3A4 inhibitor. (पोसाकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (प्रवास्टेटिन लेबल, चेतावनियां और सावधानियां)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (प्रोपाइलथायोयूरेसिल लेबल, चेतावनियां)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (फ्लुवास्टेटिन लेबल, चेतावनियां और सावधानियां)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (मेथिमाज़ोल लेबल, चेतावनियां)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (रोसुवास्टेटिन लेबल, चेतावनियां और सावधानियां)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

…Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (क्लैरिथ्रोमाइसिन लेबल, दवाओं के इंटरैक्शन)